P

Piramal Pharma Ltd
NSE:PPLPHARMA

Watchlist Manager
Piramal Pharma Ltd
NSE:PPLPHARMA
Watchlist
Price: 225.7 INR 3.04%
Market Cap: 298B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one PPLPHARMA stock under the Base Case scenario is hidden INR. Compared to the current market price of 225.7 INR, Piramal Pharma Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PPLPHARMA Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

3.5
P/S
P/S
Price to Sales
3.5
vs History
25
vs Industry
40
Median 3Y
2.3
Median 5Y
2.3
Industry
2.4
Forward
3.3
More Details
802.1
P/E
P/E
Price to Earnings
802.1
vs History
22
vs Industry
Median 3Y
287
Median 5Y
287
Industry
20.5
Forward
198.7
More Details
45.8
P/OCF
P/OCF
Price to OCF
45.8
vs History
9
vs Industry
10
Median 3Y
0
Median 5Y
0
Industry
15.4
More Details
45.8
P/FCFE
P/FCFE
Price to FCFE
45.8
vs History
9
vs Industry
7
Median 3Y
0
Median 5Y
0
Industry
22.6
More Details
3.9
P/B
P/B
Price to Book Value
3.9
vs History
9
vs Industry
26
Median 3Y
2.4
Median 5Y
2.4
Industry
2
More Details
3.6
EV/S
EV/S
Enterprise Value to Sales
3.6
vs History
25
vs Industry
35
Median 3Y
2.6
Median 5Y
2.6
Industry
2.5
Forward
3.4
More Details
5.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.7
vs History
25
vs Industry
40
Median 3Y
4.2
Median 5Y
4.2
Industry
4.9
More Details
28.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
28.9
vs History
3
vs Industry
37
Median 3Y
12.4
Median 5Y
12.4
Industry
12.6
Forward
22
More Details
28.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
28.9
vs History
3
vs Industry
35
Median 3Y
13.9
Median 5Y
13.9
Industry
15.6
Forward
45.5
More Details
47.6
EV/OCF
EV/OCF
Enterprise Value to OCF
47.6
vs History
9
vs Industry
9
Median 3Y
0
Median 5Y
0
Industry
13.9
More Details
47.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
47.6
vs History
29
vs Industry
Median 3Y
0
Median 5Y
0
Industry
17.7
More Details
2.4
EV/IC
EV/IC
Enterprise Value to IC
2.4
vs History
9
vs Industry
39
Median 3Y
1.6
Median 5Y
1.6
Industry
1.8
More Details

Multiples Across Competitors

PPLPHARMA Competitors Multiples
Piramal Pharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Piramal Pharma Ltd
NSE:PPLPHARMA
312B INR 3.5 802.1 28.9 28.9
US
Eli Lilly and Co
NYSE:LLY
819.5B USD 18.2 77.4 44.9 49.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
393B USD 4.4 27.9 13.1 17.2
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK 8 22.9 15.1 17.1
CH
Roche Holding AG
SIX:ROG
242.5B CHF 4.1 21.1 11.7 13.9
US
Merck & Co Inc
NYSE:MRK
233.7B USD 3.6 13.7 9.2 10.9
UK
AstraZeneca PLC
LSE:AZN
177.6B GBP 4.2 32.6 126.9 193.9
CH
Novartis AG
SIX:NOVN
199.6B CHF 4.4 18.9 11.4 14.7
IE
Endo International PLC
LSE:0Y5F
166.1B USD 71.6 -56.8 265.3 665.3
US
Pfizer Inc
NYSE:PFE
148.1B USD 2.3 18.4 8.7 12.5
P/E Multiple
Earnings Growth PEG
IN
P
Piramal Pharma Ltd
NSE:PPLPHARMA
Average P/E: 115
802.1
260%
3.1
US
Eli Lilly and Co
NYSE:LLY
77.4
48%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
27.9
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
22.9
19%
1.2
CH
Roche Holding AG
SIX:ROG
21.1
16%
1.3
US
Merck & Co Inc
NYSE:MRK
13.7
17%
0.8
UK
AstraZeneca PLC
LSE:AZN
32.6
36%
0.9
CH
Novartis AG
SIX:NOVN
18.9
16%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56.8 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.4
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
P
Piramal Pharma Ltd
NSE:PPLPHARMA
Average EV/EBITDA: 398.3
28.9
1%
28.9
US
Eli Lilly and Co
NYSE:LLY
44.9
30%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.1
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.1
15%
1
CH
Roche Holding AG
SIX:ROG
11.7
8%
1.5
US
Merck & Co Inc
NYSE:MRK
9.2
9%
1
UK
AstraZeneca PLC
LSE:AZN
126.9
9%
14.1
CH
Novartis AG
SIX:NOVN
11.4
5%
2.3
IE
E
Endo International PLC
LSE:0Y5F
265.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.7
3%
2.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
P
Piramal Pharma Ltd
NSE:PPLPHARMA
Average EV/EBIT: 1 702.4
28.9
-2%
N/A
US
Eli Lilly and Co
NYSE:LLY
49.6
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.2
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
17.1
16%
1.1
CH
Roche Holding AG
SIX:ROG
13.9
9%
1.5
US
Merck & Co Inc
NYSE:MRK
10.9
12%
0.9
UK
AstraZeneca PLC
LSE:AZN
193.9
21%
9.2
CH
Novartis AG
SIX:NOVN
14.7
8%
1.8
IE
E
Endo International PLC
LSE:0Y5F
665.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.5
10%
1.2

See Also

Summary
PPLPHARMA intrinsic value, competitors valuation, and company profile.
DCF Valuation
PPLPHARMA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PPLPHARMA stock valuation using valuation multiples.
Wall Street Estimates
PPLPHARMA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PPLPHARMA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 241,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.